Transcriptome analyses demonstrated that the expression levels of various cancer-drivers/oncogenes, including MYC and MYB, were negatively correlated with that of TSPX in both LNCaP cells and clinical prostate cancer samples. This evidence concerns the gene TSPYL2 and prostate carcinoma.